Wynnfeld Partners adds 292,683 shares (12.6% increase) to 2.61M position in LFCR at $4.10; stock now -40.5% from 52-week high.
Wynnfeld Partners, a 10% owner of LIFECORE BIOMEDICAL, executed 2 separate purchases on 2024-10-03 totaling 292,683 shares for $1,200,000.30 at a blended average price of $4.10, expanding its position from 2,314,750 shares to 2,607,433 shares. The stock is trading 40.5% below its 52-week high of $8.55 and has gained 6.7% over the past 30 days. LIFECORE is unprofitable (net income of $-16,230,000.00 in the latest quarter) despite 24.2% annual revenue growth, trading at a P/E of 24.24 on a market cap of $157,272,117.95. Wynnfeld's cross-ticker track record shows 20 prior open-market buys with an average 30-day return of +8.8% and a 90-day win rate of 47.37%, providing a baseline of performance but not ticker-specific evidence. The magnitude of this purchase—a 12.6% increase in holdings at a price substantially below the 52-week high—occurs as the stock has recently recovered from broader weakness, though LIFECORE's unprofitability and elevated valuation relative to its losses warrant scrutiny of the thesis underlying the accumulation.